Progyny (NASDAQ:PGNY) CFO Sells $211,012.50 in Stock

Progyny, Inc. (NASDAQ:PGNY) CFO Mark Livingston sold 8,275 shares of Progyny stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $25.50, for a total transaction of $211,012.50. Following the sale, the chief financial officer directly owned 79,063 shares in the company, valued at $2,016,106.50. The trade was a 9.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Stock Down 3.7%

Shares of PGNY traded down $0.95 during trading hours on Thursday, reaching $24.69. 1,424,301 shares of the company traded hands, compared to its average volume of 1,560,195. The company’s fifty day moving average price is $18.78 and its two-hundred day moving average price is $21.97. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of 32.06, a price-to-earnings-growth ratio of 1.31 and a beta of 0.91. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $28.75.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, May 7th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.03. The firm had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.47 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company’s revenue for the quarter was down 26.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, analysts expect that Progyny, Inc. will post 1.12 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE lifted its stake in shares of Progyny by 75.3% in the first quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock worth $20,223,000 after buying an additional 511,609 shares in the last quarter. South Dakota Investment Council raised its holdings in shares of Progyny by 20.0% during the first quarter. South Dakota Investment Council now owns 137,524 shares of the company’s stock valued at $2,335,000 after purchasing an additional 22,900 shares during the last quarter. Amundi purchased a new position in shares of Progyny during the first quarter valued at approximately $180,000. California State Teachers Retirement System raised its holdings in shares of Progyny by 30.4% during the first quarter. California State Teachers Retirement System now owns 99,753 shares of the company’s stock valued at $1,694,000 after purchasing an additional 23,273 shares during the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of Progyny by 98.0% during the first quarter. Royal Bank of Canada now owns 218,434 shares of the company’s stock valued at $3,709,000 after purchasing an additional 108,137 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PGNY. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Progyny in a research note on Friday, March 27th. Jefferies Financial Group reissued a “buy” rating and set a $30.00 price objective on shares of Progyny in a research note on Friday, March 6th. BTIG Research dropped their price objective on shares of Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Finally, KeyCorp dropped their target price on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Progyny has a consensus rating of “Moderate Buy” and a consensus price target of $29.55.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.